India Pharma Outlook Team | Thursday, 19 February 2026
Zydus Lifesciences Ltd. today announced the launch of Anyra, India’s first indigenously developed Aflibercept 2 mg biosimilar, marking a key milestone in affordable retinal care.
This new therapy targets a range of serious eye diseases, including neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema from retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV). Zydus has also signed strategic agreements with Regeneron Pharmaceuticals, Inc. and Bayer to bring this treatment to patients across India.
With more than 100 million people living with diabetes in India, cases of diabetic retinopathy continue to rise. An estimated 7–8 million individuals are affected by DR, many progressing to vision?threatening DME. Wet AMD impacts roughly 1.5–2 million elderly patients, and retinal vein occlusions affect over 2 million people nationwide. Together, these conditions create one of the largest patient pools in need of effective anti?VEGF therapy to prevent irreversible vision loss.
Also Read: Advancing Interventional Radiology in India Through Collaboration
Chronic retinal diseases often require frequent intravitreal injections over long periods. This makes treatment affordability and continuity major concerns for patients and caregivers alike. By introducing Anyra, Zydus aims to improve access to high?quality biologics, driving better treatment adherence and reducing preventable blindness in India.
Speaking on the launch, Dr. Sharvil P Patel, managing director of Zydus Lifesciences Ltd., said, “At Zydus, we are committed to making advanced biologics accessible to patients who need them most. ANYRA is a transformative step for affordable retinal care in India.”
Zydus today holds India’s largest biosimilar portfolio, with more than 13 biosimilars and complex biologic molecules developed and manufactured entirely in the country. The company’s end?to?end biologics capabilities span cell line research, process engineering, clinical trials, manufacturing, and regulatory approvals.
